EMA Reviews GSK/Vir’s COVID-19 Antibody To Support Early Use By Member States

 
• By Vibha Sharma

After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.

EU - Covid-19 Coronavirus Waving Flag
EMA Reviews Can Support Early National Decision-Making On COVID-19 Medicines • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards